07:00 , Jul 31, 2006 |  BC Week In Review  |  Company News

Nektar drug delivery news

NKTR said it closed its Bradford, U.K., site as part of a previously announced plan to divest its supercritical fluid drug delivery business. The move reduces NKTR's headcount by 35. The company said that the...
07:00 , Jul 31, 2006 |  BioCentury  |  Finance

Ebb & Flow

The $70 million financing package provided to Oscient (OSCI) by Paul Capital's Paul Royalty fund is not your typical royalty deal: instead of straight cash in exchange for royalties, it combines a mix of cash,...
07:00 , May 6, 2002 |  BC Week In Review  |  Company News

Inhale, J&J, Sheffield deal

INHL expanded its 2000 deal with JNJ's Johnson & Johnson Pharmaceutical R&D LLC subsidiary to develop supercritical fluid-based compounds. As expanded, INHL's Bradford Particle Design Ltd. subsidiary will study the use of its supercritical fluid...
07:00 , Apr 29, 2002 |  BC Extra  |  Company News

Inhale, Sheffield migraine deal

The companies partnered to develop an inhaled formulation of dihydroergotamine (DHE) to treat migraines. SHM will use its drug delivery technologies in combination with supercritical fluid technology from INHL's Bradford Particle Design subsidiary to develop...
08:00 , Jan 2, 2001 |  BC Week In Review  |  Company News

Bradford Particle, Inhale deal

INHL will acquire Bradford for $200 million, including $20 million in cash plus 3.75 million INHL shares valued at $180 million. Bradford is developing supercritical fluid processing technology that reduces from four to one the...
08:00 , Jan 2, 2001 |  BioCentury  |  Strategy

Inhale acquires a small molecule platform

Late last year, Inhale Therapeutic Systems Inc. lost out to Elan Corp. plc as the two vied to acquire Quadrant Health plc for its pulmonary delivery technology. INHL has come back with a new acquisition,...
08:00 , Dec 21, 2000 |  BC Extra  |  Company News

Inhale bids for Bradford Particle

INHL made an offer to acquire pharmaceutical manufacturer Bradford (Bradford, U.K.) for $200 million, including $20 million in cash plus 3.75 million shares valued at $180 million. The acquisition, which is expected to close in...
08:00 , Nov 20, 2000 |  BioCentury  |  Finance

Floods of paper...rainclouds looming?

Judging by the amount of money brought in last week by publicly held biotech companies, one would have difficulty discerning that the tech market (yes, including biotech) is in a nasty funk. Seven PIPEs, two...
07:00 , Aug 3, 1998 |  BC Week In Review  |  Company News

Bradford Particle Design Ltd., PowderJect deal

PJP received a non-exclusive worldwide license to Bradford's Solution Enhanced Dispersion by Supercritical fluids (SEDS) technology, which produces particles with controlled size, density and crystallinity. PJP will use SEDS with its PowderJect System, which delivers...